IGC Pharma CEO Ram Mukunda and CFO Claudia Grimaldi converted $1.15 million of company debts into 4,274,853 common shares at $0.27 per share, matching June 29 closing price. The exchange eliminates liabilities, boosts insiders’ direct equity, and signals confidence in the clinical-stage Alzheimer’s pipeline.
On July 7, 2026, IGC Pharma CEO Ram Mukunda and CFO Claudia Grimaldi canceled outstanding company debts totaling approximately $1.15M and received 4,274,853 common shares at $0.27 per share. The conversion rate matched the June 29 NYSE American closing price and required no cash outlay by the company.
Both executives converted personal cash advances and deferred compensation into restricted common stock, foregoing preferred rights or warrants. They emphasized this direct purchase as the strongest expression of confidence in IGC’s long-term Alzheimer’s therapeutic program and AI-enabled drug discovery platform.
The debt-to-equity swap eliminated $1.15M of liabilities on IGC Pharma’s balance sheet, reducing obligations without dilutive financing. It also increased insider ownership stakes and aligned management’s interests with common shareholders.
The significant insider buy-in may bolster market sentiment by demonstrating leadership’s confidence in the Phase 2 CALMA trial and broader pipeline. Investors will likely watch for subsequent clinical milestones and potential impacts on share liquidity.
